New strategies for optimizing the treatment of inflammatory dermatoses with topical corticosteroids in an era of corticosteroid-sparing regimens - 21/08/11
Doi : 10.1016/j.jaad.2005.04.025
Mark Lebwohl, MD a, ⁎ 
, Sheila Fallon Friedlander, MD b
, Sheila Fallon Friedlander, MD b a From the Department of Dermatology, Mount Sinai School of Medicine
b Departments of Medicine (Dermatology) and Pediatrics, University of California San Diego School of Medicine and Children's Hospital
Reprint requests: Mark Lebwohl, MD, Mount Sinai Medical Center, 5 E 98th St, Box 1048, New York, NY 10029.New York, New York, and San Diego, California
Le texte complet de cet article est disponible en PDF.| This supplement is supported by Connetics Corp, Palo Alto, California. This article is part of a supplement supported by Connetics Corp. Disclosure: Dr Lebwohl or members of his faculty have been investigators for Abbott, Allergan, Amgen, Biogen, Centocor, Connetics Corp, Fujisawa, Galderma, Genentech, GlaxoSmithKline, and Novartis. Dr Lebwohl has been a consultant and/or speaker for Allergan, Amgen, Biogen, Centocor, Connetics Corp, Fujisawa, and Genentech. Dr Friedlander has no financial interest in the products discussed in this article. She has served as a consultant for Connetics Corp, GlaxoSmithKline, and Novartis. |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 53 - N° 1S
P. S1-S2 - juillet 2005 Retour au numéro
Article précédent
- Table of contents
- Therapeutic options in the treatment of psoriasis and atopic dermatitis
- Alice B. Gottlieb
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?